Head to head

Apogee 9300 vs Motus AZ+ (2026)

Compare purchase costs, running costs and the evidence behind each device.

Read the comparison overview

Purchase cost: The catalog lists $120k–$160k for Motus AZ+. No new-price range is on file for Apogee 9300. Check the source notes and request current quotes.
Practice fit: Apogee 9300: alexandrite laser. Motus AZ+: dual-wavelength (in-motion). Check each model’s US regulatory status and labeled indications for your intended use.

Device A

Alexandrite laser

View full device profile →

Device B

Dual-wavelength (in-motion)

View full device profile →

Price comparison

Price comparison: Cynosure Apogee 9300 vs DEKA Motus AZ+
Attribute	Cynosure Apogee 9300	DEKA Motus AZ+
New price range	Not published	$120k–$160kSource not documented
Used asking range	$5k–$12kSource not documented	$80k–$110kSource not documented
Payback calculator	View ROI calculator	View ROI calculator
Next step	Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models. Browse current models

New price range

Cynosure Apogee 9300: Not published
DEKA Motus AZ+: $120k–$160kSource not documented

Used asking range

Cynosure Apogee 9300: $5k–$12kSource not documented
DEKA Motus AZ+: $80k–$110kSource not documented

Payback calculator

Cynosure Apogee 9300: View ROI calculator
DEKA Motus AZ+: View ROI calculator

Next step

Cynosure Apogee 9300

Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models.

Browse current models

DEKA Motus AZ+

Consumable economics

Consumable economics: Cynosure Apogee 9300 vs DEKA Motus AZ+
Attribute	Cynosure Apogee 9300	DEKA Motus AZ+
Consumable cost / lock-in	—	No per-treatment consumables — gel and eventual sapphire-tip wear; a few thousand a year in maintenance reserve.
Service cost	Not published	Not published

Consumable cost / lock-in

Cynosure Apogee 9300: —
DEKA Motus AZ+: No per-treatment consumables — gel and eventual sapphire-tip wear; a few thousand a year in maintenance reserve.

Service cost

Cynosure Apogee 9300: Not published
DEKA Motus AZ+: Not published

FDA clearance

FDA clearance: Cynosure Apogee 9300 vs DEKA Motus AZ+
Attribute	Cynosure Apogee 9300	DEKA Motus AZ+
FDA status & indication	FDA ClearedK031488, K034030 Read FDA indication wording “The Cynosure Apogee-TKS I1 Dermatological Laser is indicated for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hair regrowth after a treatment regime. It is used for all skin types (Fitzpatrick I - VI) including tanned skin. It is also indicated for the treatment of vascular lesions, benign pigmented lesions, and wrinkles.”	FDA ClearedK211821, K162886, K181486 Read FDA indication wording “Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”

FDA status & indication

Cynosure Apogee 9300: FDA ClearedK031488, K034030
Read FDA indication wording
“The Cynosure Apogee-TKS I1 Dermatological Laser is indicated for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hair regrowth after a treatment regime. It is used for all skin types (Fitzpatrick I - VI) including tanned skin. It is also indicated for the treatment of vascular lesions, benign pigmented lesions, and wrinkles.”
DEKA Motus AZ+: FDA ClearedK211821, K162886, K181486
Read FDA indication wording
“Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”

Which chains run each

Which chains run each: Cynosure Apogee 9300 vs DEKA Motus AZ+
Attribute	Cynosure Apogee 9300	DEKA Motus AZ+
Chain adoption	0 recorded pairings	0 recorded pairings
Chains using it	—	—
Approved reviews	0	0

Chain adoption

Cynosure Apogee 9300: 0 recorded pairings
DEKA Motus AZ+: 0 recorded pairings

Chains using it

Cynosure Apogee 9300: —
DEKA Motus AZ+: —

Approved reviews

Cynosure Apogee 9300: 0
DEKA Motus AZ+: 0

Specs and platform

Specs and platform: Cynosure Apogee 9300 vs DEKA Motus AZ+
Attribute	Cynosure Apogee 9300	DEKA Motus AZ+
Manufacturer	Cynosure	DEKA
Built by (OEM)	Cynosure LLC	DEKA M.E.L.A. S.r.l.
Category	Alexandrite laser	Dual-wavelength (in-motion)
Technology	755nm alexandrite (Alexandrite)	755/1064nm Moveo, higher power (Alexandrite)
Launch year	2000	2022
Status	Legacy-used-market	Current
Manufacturer source record	No linked source on file.	No linked source on file.

Manufacturer

Cynosure Apogee 9300: Cynosure
DEKA Motus AZ+: DEKA

Built by (OEM)

Cynosure Apogee 9300: Cynosure LLC
DEKA Motus AZ+: DEKA M.E.L.A. S.r.l.

Current alternatives

Current catalog models in related categories. Confirm availability and configuration with the supplier.

Lumenis OptiLIGHT

IPL platform

New: —

Cutera Xeo

Multi-app platform

New: $80k–$120k

Cutera Excel HR

Dual-wavelength laser

New: $95k–$135k

InMode Triton

Triple-wavelength diode

New: $100k–$135k

Get a free recommendation Browse by goal

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.